This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Morgan MA , Darcy KM , Rose PG , DeGeest K , Bookman MA , Aikins JK , Sill MW , Mannel RS , Allievi C , Egorin MJ , Gynecologic Oncology Group
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group
Gynecol Oncol. 2008 Sep;110(3) :329-35
PMID: 18597837 PMCID: PMC2577579
AbstractPURPOSE: To estimate the maximum tolerated dose (MTD) of paclitaxel poliglumex (PPX) in combination with carboplatin in patients with chemotherapy-naive ovarian, primary peritoneal or fallopian tube cancer, and to assess the feasibility of administering multiple cycles of this regimen. METHODS: The first 11 patients were treated in a standard 3 + 3 dose-seeking design, with carboplatin held constant at area under the curve (AUC) of 6 and PPX at 225, 175 or 135 mg/m(2). Pharmacokinetics of PPX and carboplatin were evaluated during this dose-seeking component of the trial. MTD was defined by acute dose-limiting toxicities (DLT) in the first cycle. Twenty additional evaluable patients were treated at the estimated MTD to assess the feasibility of this regimen over >or=4cycles. RESULTS: PPX at 225 mg/m(2) resulted in DLT in 2/3 patients, and was de-escalated first to 175 mg/m(2) and then to 135 mg/m(2). PPX slowly hydrolyzed to paclitaxel and did not alter the pharmacokinetics of carboplatin. DLT within the first 4-cycles were observed in 3 patients (15%) treated at the MTD: neutropenia > 2weeks (2), febrile neutropenia (1). Nineteen patients (95%) experienced grade 4 neutropenia. Sixteen patients (80%) had at least one episode of grade 3 thrombocytopenia. Three patients (15%) had grade 2 and one had grade 3 peripheral neuropathy. Complete response by CA-125 was 75%. CONCLUSIONS: The recommended dose of PPX of 135 mg/m(2) with carboplatin (AUC = 6) in newly diagnosed ovarian cancer was feasible for multiple cycles, but hematologic toxicity was greater compared with standard carboplatin and 3-hour paclitaxel.
NotesMorgan, Mark A Darcy, Kathleen M Rose, Peter G DeGeest, Koen Bookman, Michael A Aikins, James K Sill, Michael W Mannel, Robert S Allievi, Cecilia Egorin, Merrill J CA 27469/CA/NCI NIH HHS/United States CA 37517/CA/NCI NIH HHS/United States Clinical Trial, Phase I Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States Gynecologic oncology Gynecol Oncol. 2008 Sep;110(3):329-35. Epub 2008 Jul 1.